GTR Test Accession:
Help
GTR000562603.2
Last updated in GTR: 2023-01-16
View version history
GTR000562603.2, last updated: 2023-01-16
GTR000562603.1, last updated: 2021-03-03
Last annual review date for the lab: 2023-01-17
Past due
LinkOut
At a Glance
Methods (2):
Help
Molecular Genetics - Mutation scanning of the entire coding region: Bi-directional Sanger Sequence Analysis; Next-Generation (NGS)/Massively parallel sequencing (MPS)
Target population: Help
Any
Clinical validity:
Help
Not provided
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Specimen Source:
Help
- Isolated DNA
- Peripheral (whole) blood
- Saliva
- View specimen requirements
Who can order: Help
- Health Care Provider
Test Order Code:
Help
Usher Syndrome
How to Order:
Help
By requisition
Order URL
Order URL
Test service:
Help
Clinical Testing/Confirmation of Mutations Identified Previously
Comment: Pre-test and post-test genetic counseling is available for this test
Comment: Pre-test and post-test genetic counseling is available for this test
Test development:
Help
Test developed by laboratory but exempt from FDA oversight (eg. NYS CLEP approved, offered within a hospital or clinic)
Informed consent required:
Help
Based on applicable state law
Pre-test genetic counseling required:
Help
Yes
Post-test genetic counseling required:
Help
Yes
Recommended fields not provided:
Lab contact for this test,
Contact policy,
Test strategy
Conditions
Help
Total conditions: 1
Condition/Phenotype | Identifier |
---|
Test Targets
Genes
Help
Total genes: 15
Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument
Mutation scanning of the entire coding region
Bi-directional Sanger Sequence Analysis
Mutation scanning of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
SeqStudio Genetic Analyzer
Clinical Information
Test purpose:
Help
Diagnosis
Target population:
Help
Any
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
According to ACMG quide lines
According to ACMG quide lines
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes.
Yes.
Recommended fields not provided:
Clinical validity,
Clinical utility,
Are family members with defined clinical status recruited to assess significance of VUS without charge?,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
>99% sensitivity for detecting single base variants, small deletions and duplications.
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
European Molecular Genetics Quality Network, EMQN
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
European Molecular Genetics Quality Network, EMQN
VUS:
Software used to interpret novel variations
Help
HGMD, ClinVar, SIFT, Polyphen, HOPE
HGMD, ClinVar, SIFT, Polyphen, HOPE
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
Not Applicable
Additional Information
Reviews:
Clinical resources:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.